- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.01. | SciNeuro and Novartis sign global licensing deal for Alzheimer's antibody | ||
| 13.01. | JPM 26: Day 1 - drug prices and policy changes drive the agenda | ||
| 13.01. | Atara receives FDA complete response letter for Ebvallo BLA application | ||
| 12.01. | JPM26: Anthropic advances healthcare presence with new AI toolkit | ||
| 12.01. | JPM26: Eli Lilly and NVIDIA deepen ties with $1bn AI partnership | ||
| 12.01. | JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement | ||
| 12.01. | JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax | ||
| 12.01. | FDA increases manufacturing flexibility for cell and gene therapies | ||
| 12.01. | JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree | ||
| 12.01. | Novartis to build fourth US radioligand therapy facility in Florida | ||
| 12.01. | MediLink and Roche announce exclusive licensing agreement for YL201 | ||
| 09.01. | Alveus debuts in obesity arena with $160m Series A | ||
| 09.01. | J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts | ||
| 09.01. | Takeda and Halozyme sign global agreement for Enhanze technology | ||
| 09.01. | Santhera grants Agamree rights to Nxera for DMD | ||
| 08.01. | Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn | ||
| 08.01. | GSK to file for approval of twice-yearly hep B drug on positive Phase III data | ||
| 08.01. | Octapharma receives FDA approval for new Fibryga formulation in AFD | ||
| 08.01. | Day One concludes Mersana Therapeutics acquisition | ||
| 07.01. | Amgen buys Dark Blue Therapeutics in $840m oncology deal | ||
| 07.01. | Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus | ||
| 07.01. | Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis | ||
| 07.01. | Zai Lab's Augtyro receives NMPA approval for solid tumours in China | ||
| 06.01. | CDC shrinks childhood vaccine recommendation list to mirror "peer nations" | ||
| 06.01. | Takeda and Protagonist seek FDA approval for rusfertide to treat PV |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.